Androgen Deprivation-Induced Senescence Promotes Outgrowth of Androgen-Refractory Prostate Cancer Cells

Dominick G. A. Burton, Maria G. Giribaldi, Anisleidys Munoz, Katherine Halvorsen, Asmita Patel, Merce Jorda, Carlos Perez-Stable, Priyamvada Rai


    Androgen deprivation (AD) is an effective method for initially suppressing prostate cancer (PC) progression. However, androgen-refractory PC cells inevitably emerge from the androgen-responsive tumor, leading to incurable disease. Recent studies have shown AD induces cellular senescence, a phenomenon that is cell-autonomously tumor-suppressive but which confers tumor-promoting adaptations that can facilitate the advent of senescence-resistant malignant cell populations. Because androgen-refractory PC cells emerge clonally from the originally androgen-responsive tumor, we sought to investigate whether AD-induced senescence (ADIS) affects acquisition of androgen-refractory behavior in androgen-responsive LNCaP and LAPC4 prostate cancer cells. We find that repeated exposure of these androgen-responsive cells to senescence-inducing stimuli via cyclic AD leads to the rapid emergence of ADIS-resistant, androgen-refractory cells from the bulk senescent cell population. Our results show that the ADIS phenotype is associated with tumor-promoting traits, notably chemoresistance and enhanced pro-survival mechanisms such as inhibition of p53-mediated cell death, which encourage persistence of the senescent cells. We further find that pharmacologic enforcement of p53/Bax activation via Nutlin-3 prior to establishment of ADIS is required to overcome the associated pro-survival response and preferentially trigger pervasive cell death instead of senescence during AD. Thus our study demonstrates that ADIS promotes outgrowth of androgen-refractory PC cells and is consequently a suboptimal tumor-suppressor response to AD.
DOI: 10.1371/journal.pone.0068003
    Androgen deprivation (AD) is an effective method for initially suppressing prostate cancer (PC) progression. However,
    androgen-refractory PC cells inevitably emerge from the androgen-responsive tumor, leading to incurable disease. Recent

Oncogene Induced Cellular Senescence Elicits an Anti-Warburg Effect

  1. Mingxi Li1,2,†
  2. Kenneth R. Durbin2,†,
  3. Steve M. M. Sweet2
  4. Jeremiah D. Tipton3,
  5. Yupeng Zheng2,
  6. Neil L. Kelleher2,3,


Cellular senescence, an irreversible cell cycle arrest induced by a diversity of stimuli, has been considered as an innate tumor suppressing mechanism with implications and applications in cancer therapy. Using a targeted proteomics approach we show that fibroblasts induced into senescence by expression of oncogenic Ras exhibit a decrease of global acetylation on all core histones, consistent with formation of senescence-associated heterochromatic foci. We also detected clear increases in repressive markers (e.g., >50% elevation of H3K27me2/3) along with decreases in histone marks associated with increased transcriptional expression/elongation (e.g., H3K36me2/3). Despite the increases in repressive marks of chromatin, 179 loci (of 2206 total) were found to be upregulated by global quantitative proteomics. The changes in the cytosolic proteome indicated an upregulation of mitochondrial proteins and downregulation of proteins involved in glycolysis. These alterations in primary metabolism are opposite of the well-known Warburg effect observed in cancer cells. This study significantly improves our understanding of stress-induced senescence and provides a potential application for triggering it in anti-proliferative strategies that target the primary metabolism in cancer cells.

Enhanced killing of therapy-induced senescent tumor cells by oncolytic Measles vaccine viruses

  1. Timo Weiland1
  2. Johanna Lampe1
  3. Frank Essmann2
  4. Sascha Venturelli1
  5. Alexander Berger1
  6. Sascha Bossow3
  7. Susanne Berchtold1
  8. Klaus Schulze-Osthoff2
  9. Ulrich M. Lauer1,
  10. Michael Bitzer1,*


Therapy-induced senescence (TIS) as a permanent growth arrest can be induced by various stimuli, including anticancer compounds. TIS has emerged as a promising strategy to overcome resistance phenomena. However, senescent cancer cells might regain proliferation activity in vivo or even secrete tumor-promoting cytokines. Therefore, successful exploitation of TIS in cancer treatment simultaneously requires the development of effective strategies to eliminate senescent cancer cells. Virotherapy aims to selectively hit tumor cells, thus a combination with senescence-inducing drugs was explored. As a model we chose measles vaccine virus (MeV), which does not interfere with cellular senescence by itself. In different tumor cell types, such as hepatoma, pancreatic and mammary gland carcinoma, we demonstrate efficient viral replication and lysis after TIS by gemcitabine, doxorubicin or taxol. Applying real time imaging, we even found an accelerated lysis of senescent cancer cells, supporting an enhanced viral replication with an increase in cell-associated and released infectious MeV particles. In summary, we show as a proof-of-concept that senescent tumor cells can be efficiently exploited as virus host cells by oncolytic MeV. These observations open up a new field for preclinical and clinical research to further investigate TIS and oncolytic viruses as an attractive combinatorial future treatment approach.

A complex secretory program orchestrated by the inflammasome controls paracrine senescence

  • Juan Carlos Acosta,
  • Ana Banito,
  • Torsten Wuestefeld,
  • Athena Georgilis,
  • Peggy Janich,
  • Jennifer P. Morton,
  • Dimitris Athineos,
  • Tae-Won Kang,
  • Felix Lasitschka,
  • Mindaugas Andrulis,
  • Gloria Pascual,
  • Kelly J. Morris,
  • Sadaf Khan,
  • Hong Jin,
  • Gopuraja Dharmalingam,
  • Ambrosius P. Snijders,
  • Thomas Carroll,
  • David Capper,
  • Catrin Pritchard,
  • Gareth J. Inman,
  • Thomas Longerich,
  • Owen J. Sansom,
  • Salvador Aznar Benitah,
  • Lars Zender
  • Jesús Gil


Oncogene-induced senescence (OIS) is crucial for tumour suppression. Senescent cells implement a complex pro-inflammatory response termed the senescence-associated secretory phenotype (SASP). The SASP reinforces senescence, activates immune surveillance and paradoxically also has pro-tumorigenic properties. Here, we present evidence that the SASP can also induce paracrine senescence in normal cells both in culture and in human and mouse models of OIS in vivo. Coupling quantitative proteomics with small-molecule screens, we identified multiple SASP components mediating paracrine senescence, including TGF-β family ligands, VEGF, CCL2 and CCL20. Amongst them, TGF-β ligands play a major role by regulating p15INK4b and p21CIP1. Expression of the SASP is controlled by inflammasome-mediated IL-1 signalling. The inflammasome and IL-1 signalling are activated in senescent cells and IL-1α expression can reproduce SASP activation, resulting in senescence. Our results demonstrate that the SASP can cause paracrine senescence and impact on tumour suppression and senescence in vivo.

Reclassifying Cellular Senescence into Two Main Types

Persistent activation of the DNA-damage response (DDR) can trigger cells to undergo cellular senescence, a state of irreversible, immune evoking, growth arrest.  In such a way, cellular senescence can prevent tumourigenesis firstly by blocking cells from replicating and producing abnormal and potentially cancerous daughter cells and secondly by coordinating their removal by immune cells.  Additionally, senescent cells can aid tissue repair by preventing extensive cellular proliferation leading to fibrosis, possibly triggered by replication stressed-induced DNA damage.  However, if this orchestrated removal of senescent cells becomes dysregulated, then persistent senescent cells can promote tumourigenesis and tissue damage.

An aspect of the DDR in senescent cells is the induction of an array of secretory factors, including cytokines/chemokine’s, which are important in attracting/activating immune cells to their vicinity.  When immune cells reach the locality of senescent cells, they can then specifically recognize them by the expression of immune ligands on the cell membrane, a process that may also be regulated primarily by the DDR.  The specific ligands recognized and the mechanism of senescent cell death will then be dependent upon the type of immune cell interacting with the senescent cell. 

However, cells induced to undergo permanent growth arrest in vitro by the overexpression of the cyclin dependent kinase inhibitor p16ink4a, do not develop an immune evoking secretory phenotype until the addition of DNA damage.   If cells in physiological or pathological conditions can indeed undergo permanent cell cycle arrest in a p16 dependent, DDR-independent manner, then these cells are unlikely to evoke an immune response for their clearance.  In support of this, a recent study demonstrated that cells overexpressing p14(ARF) in the epidermis of mice remained present for weeks after transgene silencing (Tokarsky-Amiel et al 2013).  Even if p16-induced senescent cells do not display a pro-inflammatory phenotype, they can still cause physiological problems simply by their inability to proliferate, an essential feature required for tissue regeneration and maintenance.  In this regard, the growth arrest and pro-inflammatory phenotype of senescent cells can be investigated separately to determine which feature is important in different physiological contexts. 

Until the phenotype of p16-induced senescent cells in vivo have been researched more extensively, cellular senescence could be divided into two separate types.  Firstly, immunogenic senescence related to a DNA damage response, consisting of a pro-inflammatory phenotype and the presence of immune ligands, triggered by telomere shortening, oncogene-activation, and chemical stressors.  Secondly, sterile senescence which lacks a pro-inflammatory phenotype and the inability to evoke an immune response. 

If this distinction is made, then studies focused on the effect of cellular senescence on ageing, disease and cancer development can better design their experiments and avoid confusion between conflicting results due to differences in the types of senescence used.  

The main focus of ageing research is to prevent/combat age-related disease and disability, allowing everyone to live healthier lives for longer.